Potential effect of berberine on seizure activity and cardiac function in pentylenetetrazol-kindling seizures in rats / (Record no. 177297)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05592namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260101200104.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260101s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.M.Sc.2025.Sh.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Shrouk Mohamed Elsayed Ali Basiouny, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Potential effect of berberine on seizure activity and cardiac function in pentylenetetrazol-kindling seizures in rats / |
| Statement of responsibility, etc. | by Shrouk Mohamed Elsayed Ali Basiouny ; Supervision Dr. Hala Fahmy Zaki, Dr. Shimaa Mustafa Elshazly, Dr. Ahmed Fathi Mohamed. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | الفاعلية الممكنة للبربرين على نشاط الصرع ووظيفة القلب واحداث الأعراض بالبنتيلين تترازول في الجرذان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 126 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 101-121. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Seizures can lead to cardiac dysfunction. Multiple pathways contribute to this <br/>phenomenon, of which the chaperone sigma-1 receptor (S1R) signaling <br/>represents a promising nexus between the abnormalities seen in both epilepsy and <br/>ensuing cardiac complications. The study explored the potential of Berberine <br/>(BER), a promising S1R agonist, in treating epilepsy and associated cardiac <br/>abnormalities in a pentylenetetrazol (PTZ) kindling rat model of epilepsy. Male <br/>Wistar albino rats received PTZ (35 mg/kg) every other day alone, with BER, <br/>with phenytoin (PHT), with both BER and PHT and with both BER and an S1R <br/>blocker (NE-100) over 27 days. BER decreased seizure severity and improved <br/>hemodynamic parameters. Histopathological abnormalities were more <br/>pronounced in the PTZ, and blocker group than in other groups, in heart tissue. <br/>In cardiac tissue, BER enhanced the AKT/eNOS signaling pathway and mitigated <br/>ferroptosis by boosting the cystine/glutamate transporter/ Glutathione/ <br/>Glutathione Peroxidase 4 (XCT/GSH/GPX4) system and ferritin heavy chain-1 <br/>(FTH-1) expression, while reducing iron and Transferrin receptor protein 1 <br/>(TFR1) levels. Such effects were largely negated by NE-100 pretreatment. In <br/>conclusion, BER shows protective effects on cardiac dysfunction induced by the <br/>PTZ kindling model by acting as an S1R agonist and influencing the AKT/eNOS <br/>signaling pathway and ferroptosis. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | نوبات الصرع يمكن أن تؤدي إلى خلل في القلب. تساهم مسارات متعددة في هذه الظاهرة، حيث تمثل إشارات مستقبل الشابيرون سيغما-1 (S1R) نقطة اتصال واعدة بين الشذوذات التي تُرى في كل من الصرع والمضاعفات القلبية الناتجة عنه. استكشفت الدراسة إمكانيات البربرين (BER)، وهو ناهض واعد لمستقبلات S1R، في علاج الصرع والاضطرابات القلبية المرتبطة به في نموذج الفأر المستحث بالبينتينيلتترازول (PTZ) للصرع. تلقت ذكور الجرذان البيضاءويسترالألبينو PTZ (35 ملغ/كغ) كل يومين بمفردها، مع BER، مع الفينيتوين (PHT)، مع كل من BER وPHT ومع كل من BER ومثبط S1R (NE-100) على مدى 27 يومًا. قلل BER من شدة النوبات وحسن المعايير الديناميكية الدموية. كانت الشذوذات النسيجية المرضية أكثر وضوحًا في مجموعة PTZ ومجموعة NE-100 مقارنة بالمجموعات الأخرى، في نسيج القلب. في الأنسجة القلبية، عزز BER مسار الإشارات AKT/eNOSوقللت من الاستماتة الحديدية عن طريق تعزيز نظام ناقل السيستين/الجلوتامات/الجلوتاثيون/جلوتاثيون بيروكسيداز 4 (XCT/GSH/GPX4) وتعبير سلسلة الحديد الثقيلة للفريتين-1 (FTH-1)، بينما قللت من مستويات الحديد وبروتين مستقبل الترانسفيرين 1.(TFR1) تم إبطال هذه التأثيرات إلى حد كبير بواسطة الاستخدام المسبق بـ NE- .100 في الختام، يُظهر BER تأثيرات واقية على خلل القلب الناجم عن نموذج PTZ التحريضي من خلال العمل كمنشط لمستقبل S1R والتأثير على مسار الإشارات AKT/eNOSوالاستماتة الحديدية. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmacology and Toxicology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الأدوية والسموم |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Berberine |
| -- | epilepsy |
| -- | Sigma 1 receptor |
| -- | cardiac dysfunction |
| -- | AKT/eNOS signaling |
| -- | ferroptosis |
| -- | البربرين |
| -- | الصرع |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hala Fahmy Zaki |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shimaa Mustafa Elshazly |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ahmed Fathi Mohamed. |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Hala Fahmy Zaki |
| -- | Shimaa Mustafa Elshazly |
| -- | Ahmed Fathi Mohamed |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology and Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 01.01.2026 | 93020 | Cai01.08.09.M.Sc.2025.Sh.P | 01010110093020000 | 01.01.2026 | 01.01.2026 | Thesis |